Cumulus Neuroscience raises £3.25M for at-home EEG platform in neuroscience clinical trials
Summary
Cumulus Neuroscience has raised £3.25 million in funding to advance its integrated physiological and digital biomarker platform for neuroscience clinical trials. The Belfast-based company combines a proprietary dry-electrode EEG headset with AI-powered analytics to enable remote, at-home monitoring of brain activity and cognitive function, improving clinical trial efficiency for CNS therapies.
Why it matters
Clinical trials in neurology are difficult and expensive, with largely disappointing results partly due to limitations in clinical trial methodology. Cumulus's platform enables frequent at-home EEG monitoring as an effective way to track disease progression, potentially accelerating development of new treatments for Alzheimer's, depression, and schizophrenia while reducing trial costs.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial